| **DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION** | **DRUG TYPE AND USE** | **LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION** | **PBAC OUTCOME** |
| --- | --- | --- | --- |
| EPINEPHRINEI.M Injection, 150 micrograms in 0.3 mL, pen deviceI.M Injection, 300 micrograms in 0.3 mL, pen deviceSymjepi® Emerge Health Pty LtdNew listing (Minor Submission)  | Acute allergic reactions including anaphylaxis | To request the Authority Required PBS listing of Symjepi® for the emergency treatment of allergic reactions. | The PBAC recommendation cannot be made public until the TGA outcome is known. |
| NIVOLUMAB + IPILIMUMABNivolumab:Injection concentrate for I.V. infusion 40 mg in 4 mLInjection concentrate for I.V. infusion 100 mg in 10 mLOpdivo®Ipilimumab:Injection concentrate for I.V. infusion 50 mg in 10 mLYervoy®Bristol-Myers Squibb Australia Pty LtdNew listing(Major Submission) | Non-small cell lung cancer (NSCLC) | To request an extension to the current Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listings for nivolumab and ipilimumab to include the first-line treatment of patients with Stage IV NSCLC.  | The PBAC recommendation cannot be made public until the TGA outcome is known. |